By Frederick R. Appelbaum MD (auth.), Mary J. Laughlin MD, Hillard M. Lazarus MD (eds.)
Read or Download Allogeneic Stem Cell Transplantation: Clinical Research and Practice PDF
Similar clinical books
This concise pocket consultant to urological investigative approaches stories the indicators and pitfalls of exams sooner than they're asked and indicates which checks may be played in person urological stipulations. half I describes the rules, technique, benefits and drawbacks of every of the investigations and covers all urological investigations/tests.
1 2 D. FITZGERALDI, I. PASTAN , and J. ROBERTUS creation . . . . . . . . . . . . . I 2 Toxin Structure-Function homes 2 2. 1 capabilities. . . . . . . . . . . . . . . . . . . . . . . . 2 2. 2 Binding. . . . . . . . . . . . . . . . . . . . . . . . . three three Intracellular Processing - Cleavage and aid .
- Bisphosphonates in Clinical Oncology: The Development of Pamidronate (Recent Results in Cancer Research)
- Functional Reconstruction of the Mandible: Experimental Foundations and Clinical Experience, 1st Edition
- Clinical Psychology and Medicine: A Behavioral Perspective
- Essential Urology: A Guide to Clinical Practice
Additional resources for Allogeneic Stem Cell Transplantation: Clinical Research and Practice
Conversely, patients who are BCR/ABL+ following transplantation seem to be at high risk for subsequent relapse. 025) (48). The prognostic significance of the PCR assay remained after controlling for other variables that could influence relapse risk. The risk of relapse was greater for patients with a p190 fusion transcript than for those with p210 BCR/ABL. The median time from detection of a positive PCR result to relapse was 94 d. Additional insights into the kinetics of disappearance of BCR/ABL will be obtained from current studies using real-time PCR techniques to quantify transcript number reproducibly (49,50).
EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology. Basic Principles and Practice, 3rd ed. Churchill Livingstone, New York, 2000, pp. 1106–1129. 25. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–199. 26. Pedersen-Bjergaard J. Radiotherapy-and-chemotherapy-induced myelodysplasia and acute myeloid leukemia: a review. Leuk Res 1992;16:61–65. 27. Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin’s disease.
Blood 1996;87:51–58. 55. O’Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 1995;13:2973–2979. 56. De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group. Br J Haematol 1990;74:151–155. 57. Runde V, de Witte T, Arnold R, et al.